Sort
4,870 grants matching “glp 1”
Development of Dual GABAA and alpah7 Nicotinic Receptor Modulators for AD
$495,936Kelvin W Gee · University Of California-Irvine · U01 · FY2010 · AG
Animal models to assess efficacy of countermeasures for SM-induced toxicity
$495,840Janet M. Benson · Lovelace Biomedical & Environmental Research Institute · U54 · FY2007 · NS
Metabolism of islets of langerhans and hormone release
$494,997Franz M Matschinsky · University Of Pennsylvania · R01 · FY2008 · DK
Quantitation of Factors Regulating Glucose Tolerance
$494,869Richard N. Bergman · University Of Southern California · R01 · FY2006 · DK
Therapeutic targets in African-American youth with type 2 diabetes
$494,644Stephanie Therese Chung · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK
A secure analytics platform to study the prognosis of people with HIV in the USA, Canada and Europe and comparative effectiveness of treatment regimens: the Antiretroviral Therapy Cohort Collaboration
$494,632Jonathan Sterne · University Of Bristol · R01 · FY2024 · AI
Structure-based Drug Discovery for the GLP-1 Receptor
$494,338Bingfa Sun · Confometrx, Inc. · R44 · FY2017 · DK
Quantitation of Factors Regulating Glucose Tolerance
$494,242Richard N. Bergman · University Of Southern California · R01 · FY2007 · DK
A Shear Force Transfer Coupling for Soft Tissue Repair
$493,118David B Melvin · Cardioenergetics, Inc. · R44 · FY2007 · EB
Neurohumoral Regulation in Diabetic Enteropathy
$492,900Adil E. Bharucha · Mayo Clinic Rochester · P01 · FY2016 · DK
Neurohumoral Regulation in Diabetic Enteropathy
$492,900Adil E. Bharucha · Mayo Clinic Rochester · P01 · FY2019 · DK
Neurohumoral Regulation in Diabetic Enteropathy
$492,900Adil E. Bharucha · Mayo Clinic Rochester · P01 · FY2015 · DK
Neurohumoral Regulation in Diabetic Enteropathy
$492,900Adil E. Bharucha · Mayo Clinic Rochester · P01 · FY2017 · DK
Neurohumoral Regulation in Diabetic Enteropathy
$492,900Adil E. Bharucha · Mayo Clinic Rochester · P01 · FY2018 · DK
Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome [IND 121109 acknowledged 8/27/14]
$492,648Eric Hollander · Albert Einstein College Of Medicine, Inc · R01 · FY2017 · FD
Targeted Nanoparticles of Bismuth Organo Complexes for Spectral CT Imaging of Cor
$492,514Y Andrew Wang · Ocean Nanotech, Llc · R42 · FY2015 · HL
Semaglutide for the treatment of opioid use disorder: A pilot randomized controlled trial
$492,250Joji Suzuki · Brigham And Women'S Hospital · R21 · FY2024 · DA
Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancer
$492,046Zhenkun Lou · Mayo Clinic Rochester · R01 · FY2025 · CA
University of Maryland, Baltimore Biomarker Reference Laboratory
$491,976Sanford A Stass · University Of Maryland Baltimore · U24 · FY2013 · CA
Validation of a Human In Vitro Vaginal Irritation Test
$491,867Seyoum Ayehunie · Mattek Corporation · R44 · FY2010 · HD
Development of an intravascular circulatory support device for high-risk for percutaneous coronary intervention and cardiogenic shock
$491,583Jeffrey Larose · Rt Cardiac Systems, Inc. · R43 · FY2020 · HL
Glucagon-like peptide-1 agonist effects on energy balance in hypothalamic obesity
$491,489Christian Ludwig Roth · Seattle Children'S Hospital · R01 · FY2017 · DK
Metabolism of islets of langerhans and hormone release
$490,790Franz M Matschinsky · University Of Pennsylvania · R01 · FY2011 · DK
The Chesapeake-Ohio Pharmacokinetics Core for The ETCTN
$489,830Jan Hendrik Beumer · Johns Hopkins University · U24 · FY2024 · CA
Glucagon-like peptide-1 agonist effects on energy balance in hypothalamic obesity
$489,637Christian Ludwig Roth · Seattle Children'S Hospital · R01 · FY2016 · DK